{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:48:17Z","timestamp":1792597697658,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":93,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Research Council of Thailand (NRCT) and Chiang Mai University","award":["N42A680105"],"award-info":[{"award-number":["N42A680105"]}]},{"name":"National Research Council of Thailand","award":["N42A680423"],"award-info":[{"award-number":["N42A680423"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04431-x","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T11:15:13Z","timestamp":1784546113000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma"],"prefix":"10.1007","volume":"75","author":[{"given":"Ratchaneewan","family":"Sumankan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prin","family":"Sungwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natthanich","family":"Boonsatit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3124-5206","authenticated-orcid":false,"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3634-1881","authenticated-orcid":false,"given":"Aussara","family":"Panya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"4431_CR1","doi-asserted-by":"publisher","first-page":"117822421986823","DOI":"10.1177\/1178224219868235","volume":"13","author":"SA Bird","year":"2019","unstructured":"Bird SA, Boyd K (2019) Multiple myeloma: an overview of management. Palliat Care Soc Pract 13:1178224219868235. https:\/\/doi.org\/10.1177\/1178224219868235","journal-title":"Palliat Care Soc Pract"},{"key":"4431_CR2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, Tuazon S, Gopal AK, Libby EN (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327:464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"key":"4431_CR3","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.Ccr-16-0868","volume":"22","author":"SK Kumar","year":"2016","unstructured":"Kumar SK, Anderson KC (2016) Immune therapies in multiple myeloma. Clin Cancer Res 22:5453\u20135460. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-16-0868","journal-title":"Clin Cancer Res"},{"key":"4431_CR4","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV (2024) Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99:1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422","journal-title":"Am J Hematol"},{"key":"4431_CR5","doi-asserted-by":"publisher","DOI":"10.1177\/20406207241237594","author":"S Yuan","year":"2024","unstructured":"Yuan S, Chen Y, Liu H (2024) Progress and prospect of ASCT combined with CAR-T therapy in the treatment of multiple myeloma. Ther Adv Hematol. https:\/\/doi.org\/10.1177\/20406207241237594","journal-title":"Ther Adv Hematol"},{"key":"4431_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G (2024) Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J 14:158. https:\/\/doi.org\/10.1038\/s41408-024-01139-y","journal-title":"Blood Cancer J"},{"key":"4431_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020407","author":"V Pinto","year":"2020","unstructured":"Pinto V, Bergantim R, Caires HR, Seca H, Guimar\u00e3es JE, Vasconcelos MH (2020) Multiple myeloma: available therapies and causes of drug resistance. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12020407","journal-title":"Cancers (Basel)"},{"key":"4431_CR8","doi-asserted-by":"publisher","first-page":"106949","DOI":"10.1016\/j.leukres.2022.106949","volume":"122","author":"Y Yue","year":"2022","unstructured":"Yue Y, Cao Y, Wang F et al (2022) Bortezomib-resistant multiple myeloma patient-derived xenograft is sensitive to anti-CD47 therapy. Leuk Res 122:106949. https:\/\/doi.org\/10.1016\/j.leukres.2022.106949","journal-title":"Leuk Res"},{"key":"4431_CR9","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s13045-021-01197-w","volume":"14","author":"Z Jiang","year":"2021","unstructured":"Jiang Z, Sun H, Yu J, Tian W, Song Y (2021) Targeting CD47 for cancer immunotherapy. J Hematol Oncol 14:180. https:\/\/doi.org\/10.1186\/s13045-021-01197-w","journal-title":"J Hematol Oncol"},{"key":"4431_CR10","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.227579","author":"N Rastgoo","year":"2019","unstructured":"Rastgoo N, Wu J, Liu M, Pourabdollah M, Atenafu E, Reece D, Chen W, Chang H (2019) Targeting CD47\/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2019.227579","journal-title":"Haematologica"},{"key":"4431_CR11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-020-00930-1","volume":"13","author":"E Eladl","year":"2020","unstructured":"Eladl E, Tremblay-LeMay R, Rastgoo N, Musani R, Chen W, Liu A, Chang H (2020) Role of CD47 in hematological malignancies. J Hematol Oncol 13:96. https:\/\/doi.org\/10.1186\/s13045-020-00930-1","journal-title":"J Hematol Oncol"},{"key":"4431_CR12","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","volume":"13","author":"R Maute","year":"2022","unstructured":"Maute R, Xu J, Weissman IL (2022) CD47-SIRP\u03b1-targeted therapeutics: status and prospects. Immunooncol Technol 13:100070. https:\/\/doi.org\/10.1016\/j.iotech.2022.100070","journal-title":"Immunooncol Technol"},{"key":"4431_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2217\/fon-2022-0975","volume":"19","author":"B Paul","year":"2023","unstructured":"Paul B, Liedtke M, Khouri J et al (2023) A phase II multi-arm study of magrolimab combinations in patients with relapsed\/refractory multiple myeloma. Future Oncol 19:7\u201317. https:\/\/doi.org\/10.2217\/fon-2022-0975","journal-title":"Future Oncol"},{"key":"4431_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1182\/blood-2020-139655","volume":"136","author":"WC Wilson","year":"2020","unstructured":"Wilson WC, Richards J, Puro RJ et al (2020) AO-176, a highly differentiated clinical stage anti-CD47 antibody, exerts potent anti-tumor activity in preclinical models of multiple myeloma as a single agent and in combination with approved therapeutics. Blood 136:3\u20134. https:\/\/doi.org\/10.1182\/blood-2020-139655","journal-title":"Blood"},{"key":"4431_CR15","doi-asserted-by":"publisher","first-page":"109168","DOI":"10.1016\/j.clim.2022.109168","volume":"246","author":"E Roshandel","year":"2023","unstructured":"Roshandel E, Ghaffari-Nazari H, Mohammadian M, Salimi M, Abroun S, Mirfakhraie R, Hajifathali A (2023) NK cell therapy in relapsed refractory multiple myeloma. Clin Immunol 246:109168. https:\/\/doi.org\/10.1016\/j.clim.2022.109168","journal-title":"Clin Immunol"},{"key":"4431_CR16","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","volume":"35","author":"US Arvindam","year":"2021","unstructured":"Arvindam US, van Hauten PMM, Schirm D et al (2021) A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia 35:1586\u20131596. https:\/\/doi.org\/10.1038\/s41375-020-01065-5","journal-title":"Leukemia"},{"key":"4431_CR17","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1182\/blood.2022016200","volume":"141","author":"MM Berrien-Elliott","year":"2023","unstructured":"Berrien-Elliott MM, Jacobs MT, Fehniger TA (2023) Allogeneic natural killer cell therapy. Blood 141:856\u2013868. https:\/\/doi.org\/10.1182\/blood.2022016200","journal-title":"Blood"},{"key":"4431_CR18","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/978-1-4939-3684-7_28","volume":"1441","author":"M Felices","year":"2016","unstructured":"Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA (2016) Generation of BiKEs and TriKEs to improve NK cell-mediated targeting of tumor cells. Methods Mol Biol 1441:333\u2013346. https:\/\/doi.org\/10.1007\/978-1-4939-3684-7_28","journal-title":"Methods Mol Biol"},{"key":"4431_CR19","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1007\/s10637-025-01568-x","volume":"43","author":"C Chiawpanit","year":"2025","unstructured":"Chiawpanit C, Wutti-In Y, Wongpalee SP et al (2025) Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer. Invest New Drugs 43:874\u2013884. https:\/\/doi.org\/10.1007\/s10637-025-01568-x","journal-title":"Invest New Drugs"},{"key":"4431_CR20","doi-asserted-by":"publisher","first-page":"112612","DOI":"10.1016\/j.intimp.2024.112612","volume":"138","author":"J Panaampon","year":"2024","unstructured":"Panaampon J, Sungwan P, Fujikawa S, Sampattavanich S, Jirawatnotai S, Okada S (2024) Trastuzumab, a monoclonal anti-HER2 antibody modulates cytotoxicity against cholangiocarcinoma via multiple mechanisms. Int Immunopharmacol 138:112612. https:\/\/doi.org\/10.1016\/j.intimp.2024.112612","journal-title":"Int Immunopharmacol"},{"key":"4431_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1111\/1348-0421.12355","volume":"60","author":"S Hattori","year":"2016","unstructured":"Hattori S, Matsuda K, Kariya R, Harada H, Okada S (2016) Proliferation of functional human natural killer cells with anti-HIV-1 activity in NOD\/SCID\/Jak3(null) mice. Microbiol Immunol 60:106\u2013113. https:\/\/doi.org\/10.1111\/1348-0421.12355","journal-title":"Microbiol Immunol"},{"key":"4431_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00262-021-03054-8","volume":"71","author":"J Panaampon","year":"2022","unstructured":"Panaampon J, Kariya R, Okada S (2022) Efficacy and mechanism of the anti-CD38 monoclonal antibody Daratumumab against primary effusion lymphoma. Cancer Immunol Immunother 71:1017\u20131031. https:\/\/doi.org\/10.1007\/s00262-021-03054-8","journal-title":"Cancer Immunol Immunother"},{"key":"4431_CR23","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1016\/j.ejca.2014.03.004","volume":"50","author":"H Goto","year":"2014","unstructured":"Goto H, Kojima Y, Matsuda K, Kariya R, Taura M, Kuwahara K, Nagai H, Katano H, Okada S (2014) Efficacy of anti-CD47 antibody-mediated phagocytosis with macrophages against primary effusion lymphoma. Eur J Cancer 50:1836\u20131846. https:\/\/doi.org\/10.1016\/j.ejca.2014.03.004","journal-title":"Eur J Cancer"},{"key":"4431_CR24","doi-asserted-by":"publisher","first-page":"539748","DOI":"10.1155\/2011\/539748","volume":"2011","author":"A Ono","year":"2011","unstructured":"Ono A, Hattori S, Kariya R, Iwanaga S, Taura M, Harada H, Suzu S, Okada S (2011) Comparative study of human hematopoietic cell engraftment into BALB\/c and C57BL\/6 strain of rag-2\/jak3 double-deficient mice. J Biomed Biotechnol 2011:539748. https:\/\/doi.org\/10.1155\/2011\/539748","journal-title":"J Biomed Biotechnol"},{"key":"4431_CR25","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C et al (2010) Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell 142:699\u2013713. https:\/\/doi.org\/10.1016\/j.cell.2010.07.044","journal-title":"Cell"},{"key":"4431_CR26","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/j.1365-2141.2007.06729.x","volume":"138","author":"JM Rendtlew Danielsen","year":"2007","unstructured":"Rendtlew Danielsen JM, Knudsen LM, Dahl IM, Lodahl M, Rasmussen T (2007) Dysregulation of CD47 and the ligands thrombospondin 1 and 2 in multiple myeloma. Br J Haematol 138:756\u2013760. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06729.x","journal-title":"Br J Haematol"},{"key":"4431_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020305","author":"J Sun","year":"2020","unstructured":"Sun J, Muz B, Alhallak K et al (2020) Targeting CD47 as a novel immunotherapy for multiple myeloma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12020305","journal-title":"Cancers (Basel)"},{"key":"4431_CR28","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/leu.2012.141","volume":"26","author":"D Kim","year":"2012","unstructured":"Kim D, Wang J, Willingham SB, Martin R, Wernig G, Weissman IL (2012) Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells. Leukemia 26:2538\u20132545. https:\/\/doi.org\/10.1038\/leu.2012.141","journal-title":"Leukemia"},{"key":"4431_CR29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200839","author":"T Deuse","year":"2021","unstructured":"Deuse T, Hu X, Agbor-Enoh S et al (2021) The SIRP\u03b1-CD47 immune checkpoint in NK cells. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20200839","journal-title":"J Exp Med"},{"key":"4431_CR30","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/bjc.1998.518","volume":"78","author":"MP Velders","year":"1998","unstructured":"Velders MP, van Rhijn CM, Oskam E, Fleuren GJ, Warnaar SO, Litvinov SV (1998) The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas. Br J Cancer 78:478\u2013483. https:\/\/doi.org\/10.1038\/bjc.1998.518","journal-title":"Br J Cancer"},{"key":"4431_CR31","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3389\/fimmu.2019.02237","volume":"10","author":"SQ Nagelkerke","year":"2019","unstructured":"Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW (2019) Genetic variation in low-to-medium-affinity Fc\u03b3 receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front Immunol 10:2237. https:\/\/doi.org\/10.3389\/fimmu.2019.02237","journal-title":"Front Immunol"},{"key":"4431_CR32","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1084\/jem.171.4.1333","volume":"171","author":"CL Anderson","year":"1990","unstructured":"Anderson CL, Shen L, Eicher DM, Wewers MD, Gill JK (1990) Phagocytosis mediated by three distinct Fc gamma receptor classes on human leukocytes. J Exp Med 171:1333\u20131345. https:\/\/doi.org\/10.1084\/jem.171.4.1333","journal-title":"J Exp Med"},{"key":"4431_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/019262339902700123","volume":"27","author":"LH Arp","year":"1999","unstructured":"Arp LH (1999) Tumor models: assessing toxicity in efficacy studies. Toxicol Pathol 27:121\u2013122. https:\/\/doi.org\/10.1177\/019262339902700123","journal-title":"Toxicol Pathol"},{"key":"4431_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s40364-022-00373-5","volume":"10","author":"T Qu","year":"2022","unstructured":"Qu T, Li B, Wang Y (2022) Targeting CD47\/SIRP\u03b1 as a therapeutic strategy, where we are and where we are headed. Biomark Res 10:20. https:\/\/doi.org\/10.1186\/s40364-022-00373-5","journal-title":"Biomark Res"},{"key":"4431_CR35","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.canlet.2015.02.036","volume":"360","author":"Z Xiao","year":"2015","unstructured":"Xiao Z, Chung H, Banan B et al (2015) Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma. Cancer Lett 360:302\u2013309. https:\/\/doi.org\/10.1016\/j.canlet.2015.02.036","journal-title":"Cancer Lett"},{"key":"4431_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12092659","author":"DA Vallera","year":"2020","unstructured":"Vallera DA, Ferrone S, Kodal B et al (2020) NK-cell-mediated targeting of various solid tumors using a B7-H3 tri-specific killer engager in vitro and in vivo. Cancers. https:\/\/doi.org\/10.3390\/cancers12092659","journal-title":"Cancers"},{"key":"4431_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-SITC2021.444","author":"M Felices","year":"2021","unstructured":"Felices M, Warlick E, Juckett M et al (2021) 444\u2005GTB-3550 tri-specific killer engager TriKE\u2122 drives NK cells expansion and cytotoxicity in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients. J ImmunoTher Cancer. https:\/\/doi.org\/10.1136\/jitc-2021-SITC2021.444","journal-title":"J ImmunoTher Cancer"},{"key":"4431_CR38","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1038\/s41598-018-24897-9","volume":"8","author":"M Kuna","year":"2018","unstructured":"Kuna M, Mahdi F, Chade AR, Bidwell GL 3rd (2018) Molecular size modulates pharmacokinetics, biodistribution, and renal deposition of the drug delivery biopolymer elastin-like polypeptide. Sci Rep 8:7923. https:\/\/doi.org\/10.1038\/s41598-018-24897-9","journal-title":"Sci Rep"},{"key":"4431_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1158\/1535-7163.MCT-25-0425","volume":"25","author":"H Zhang","year":"2026","unstructured":"Zhang H, He F, Cao L et al (2026) A novel anti-CD47 antibody TJH2201: efficacious tumor suppression with reduced RBC toxicity via a SIRP\u03b1-independent mechanism. Mol Cancer Ther 25:21\u201333. https:\/\/doi.org\/10.1158\/1535-7163.MCT-25-0425","journal-title":"Mol Cancer Ther"},{"key":"4431_CR40","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","volume":"32","author":"A Russ","year":"2018","unstructured":"Russ A, Hua AB, Montfort WR et al (2018) Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRP\u03b1 in hematological malignancies, an in-depth review. Blood Rev 32:480\u2013489. https:\/\/doi.org\/10.1016\/j.blre.2018.04.005","journal-title":"Blood Rev"},{"key":"4431_CR41","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1200\/jco.18.02018","volume":"37","author":"BI Sikic","year":"2019","unstructured":"Sikic BI, Lakhani N, Patnaik A et al (2019) First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol 37:946\u2013953. https:\/\/doi.org\/10.1200\/jco.18.02018","journal-title":"J Clin Oncol"},{"key":"4431_CR42","doi-asserted-by":"publisher","first-page":"e0137345","DOI":"10.1371\/journal.pone.0137345","volume":"10","author":"J Liu","year":"2015","unstructured":"Liu J, Wang L, Zhao F et al (2015) Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS ONE 10:e0137345. https:\/\/doi.org\/10.1371\/journal.pone.0137345","journal-title":"PLoS ONE"},{"key":"4431_CR43","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP (2000) Role of CD47 as a marker of self on red blood cells. Science 288:2051\u20132054. https:\/\/doi.org\/10.1126\/science.288.5473.2051","journal-title":"Science"},{"key":"4431_CR44","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1158\/1535-7163.MCT-12-0692","volume":"11","author":"MK Gleason","year":"2012","unstructured":"Gleason MK, Verneris MR, Todhunter DA et al (2012) Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 11:2674\u20132684. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0692","journal-title":"Mol Cancer Ther"},{"key":"4431_CR45","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.smim.2017.07.011","volume":"31","author":"ZB Davis","year":"2017","unstructured":"Davis ZB, Vallera DA, Miller JS, Felices M (2017) Natural killer cells unleashed: checkpoint receptor blockade and BiKE\/TriKE utilization in NK-mediated anti-tumor immunotherapy. Semin Immunol 31:64\u201375. https:\/\/doi.org\/10.1016\/j.smim.2017.07.011","journal-title":"Semin Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04431-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04431-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:02:11Z","timestamp":1792594931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04431-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":45,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["4431"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04431-x","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"31 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"252"}}